Word: weisbrode
(lookup in dictionary)
(lookup stats)
Dates: all
Sort By: most recent first
(reverse)
...course, back in reality, the logo isn’t going to be changed, Orlando Magic general manager John Weisbrod ’91 has since traded away McGrady for various Houston Rockets, and Howard, for what it’s worth by way of “toughness,” still wears braces...
...manages to instill new management intensity in the industry, biotech will remain a dicey game. Only one drug in 5,000 screened makes it to market. "We'll take the risk that a company fails to execute its plan once it has a drug approval," says Stuart Weisbrod, chief investment officer of Merlin Biomed, a health-care hedge fund. "What we don't want is the risk that their product doesn't work." The uncertainty of drug research - it can take 12 years to bring a new medicine to market - is what drives the industry's volatility. Biotech stocks soared...
...will remain a dicey game. Only one drug in 5,000 screened makes it to market, and even seasoned health-care investors are reluctant to handicap the process. "We'll take the risk that a company fails to execute its plan once it has a drug approval," says Stuart Weisbrod, chief investment officer of Merlin Biomed, a health-care hedge fund. "What we don't want is the risk that their product doesn't work." The uncertainty of drug research--it can take 12 years to bring a new medicine to market--is what drives the industry's volatility...
...adds up to big changes in an industry prone to speculative excess. Investors still shouldn't touch these stocks outside a mutual fund or without diversifying across at least five companies. Given the sharp run-up this year, Weisbrod's hedge fund has cut its biotech holdings a third, and six top executives at Genentech recently sold $36 million of the stock. The relatively stodgy feel of the Biogen-IDEC deal has still other growth investors running for the hills. It's all part of growing up--and part of Mullen's plan. --With reporting by Eric Roston/Washington and Unmesh...
Biotech companies are notorious for moving ahead with tests too quickly. But, Weisbrod notes, "that still doesn't account for this huge discrepancy." His top picks, too, expect to have drugs approved within two years: Biochem Pharma (hepatitis) and Centocor (blood clots). Another fan of companies with late-stage drugs is Evan Sturza, editor of Sturza's Medical Investment Letter, whose top picks are Aviron (flu), Gilead Sciences (HIV, hepatitis) and Sepracor (side effects from Prozac, Claritin and others...